Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets trading flat
Wed, 5 Mar 11:30 am

With heavy weight indices losing favor, Indian equity markets have lost grounds during the post morning trading session. With elections on the threshold, the markets are trading on a flat note. The stocks from consumer durables and automobiles are witnessing the maximum selling pressures, while the healthcare stocks are trading firm.

The BSE-Sensex is trading down by 25 points and the NSE-Nifty is trading down by 8 points. The BSE Mid Cap index is trading up 0.4% and the BSE Small Cap index is trading higher by 0.1%. The rupee is trading at 61.9 to the US dollar.

Telecom stocks are trading mixed. Bharti Airtel and Reliance Comm. are leading the pack of losers, whereas Tata Teleservices is trading firm.

As per a leading business daily, Bharti Infratel the telecom tower infrastructure arm of Bharti Airtel, has signed a tower sharing pact with Reliance Jio Infocomm. Bharti Infratel has over 82,000 telecom towers, which includes its own towers and from its 42 per cent equity interest in Indus Towers. The arrangement is master sharing agreement which includes inter and intra city optic fibre network, submarine cable networks, towers and other such opportunities identified in the future. The pricing would also be decided based on the prevalent market rates. Reliance Jio is the telecom arm of Reliance Industries, that has the pan India 4G license and has also won the voice spectrum license in the recent spectrum auction. Reliance Jio is likely to launch its 4G services by September this year in the city of Delhi and Mumbai. The stock of Bharti Infratel is trading higher by 5% today.

MNC pharma stocks are trading mixed today. While Merck Ltd. is trading firm, stocks such as Pfizer and Novartis are trading on a weak note.

As per a leading business daily, Novartis India's parent is expected to face penalty for submitting a fake document to Drug Controller General of India (DCGI) with respect to registration of its site plant for the drug, Tiamulin Hydrogen Fumarate. Novartis India has admitted the same before DCGI and tendered unconditional apology. The move would also affect Novartis India's business as regulator has cancelled the import license and registration for the drug and ordered its immediate recall from the market. The drug is used for respiratory problems in animals. The matter of furnishing a fake certificate to get registration of a drug has also been forwarded to the health ministry for further legal action.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets trading flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.